Loading...
•
Sep 30, 2024
Zimmer Biomet Q3 2024 Earnings Report
Reported a 4.0% increase in net sales and adjusted diluted earnings per share of $1.74.
Key Takeaways
Zimmer Biomet reported a strong third quarter with net sales of $1.824 billion, a 4.0% increase over the prior year. Diluted earnings per share were $1.23, and adjusted diluted earnings per share were $1.74. The company has updated its 2024 financial guidance, reducing and narrowing the range for the full-year outlook.
Third quarter net sales increased 4.0% to $1.824 billion, or 4.1% on a constant currency basis.
Third quarter diluted earnings per share were $1.23; adjusted diluted earnings per share were $1.74.
The company announced plans for the broad commercial launch of the Z1™ Femoral Hip System.
Zimmer Biomet completed the acquisition of OrthoGrid Systems Inc.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company is updating its full-year 2024 financial guidance to reduce and narrow its previous projected ranges for revenue growth and adjusted diluted EPS.
Positive Outlook
- 2024 Reported Revenue Change: 3.5% - 4.0%
- Foreign Currency Exchange Impact: (0.75)%
- 2024 Constant Currency Revenue Change: 4.25% - 4.75%
- Adjusted Diluted EPS: $7.95 - $8.05
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...